Avacincaptad pegol
| Names | |
|---|---|
| Trade names | Izervay |
| Other names | Zimura |
| Clinical data | |
| Drug class | Complement inhibitor |
| Routes of use | Intravitreal |
| Legal | |
| License data | |
| Legal status | |
| Chemical and physical data | |
| Formula | C395H453F21N142Na39O262P39 |
| Molar mass | 13885.245 g·mol−1 |
Avacincaptad pegol, sold under the brand name Izervay, is a medication used to treat age-related macular degeneration.[1]
It is a complement inhibitor.[1]
Avacincaptad pegol was approved for medical use in the United States in 2023.[2]
Medical uses
Avacincaptad pegol is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration.[3]
Society and culture
Avacincaptad pegol is the international nonproprietary name.[4]
References
- ↑ 1.0 1.1 1.2 "Izervay- avacincaptad pegol injection". DailyMed. 9 August 2023. Archived from the original on 26 August 2023. Retrieved 25 August 2023.
- ↑ "Novel Drug Approvals for 2023". U.S. Food and Drug Administration (FDA). 18 August 2023. Archived from the original on 21 January 2023. Retrieved 25 August 2023.
This article incorporates text from this source, which is in the public domain.
- ↑ "Drug Approval Package: Izervay". U.S. Food and Drug Administration (FDA). 1 September 2023. Archived from the original on 20 November 2023. Retrieved 20 November 2023.
- ↑ World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information. 30 (1). hdl:10665/331046.
External links
| Identifiers: |
|---|
- Clinical trial number NCT02686658 for "Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration" at ClinicalTrials.gov
- Clinical trial number NCT04435366 for "A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)" at ClinicalTrials.gov